Ergoteles’s Phio Pharmaceuticals PHIO Stock Holding History

Ergoteles’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-115	Closed	-$7K	–	1782
2022 Q3	$7K	Buy	+115	New	+$8.71K	﹤0.01%	1482

Other funds holding PHIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ergoteles's PHIO Position: Q4 2022 in Review

Ergoteles sold out of Phio Pharmaceuticals (PHIO) in Q4 2022, closing a stake of 115 shares — an estimated $7K sold.

Ergoteles first reported a position in PHIO in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 10 funds tracked by Wall St. Rank hold PHIO as of Q4 2022.

Ergoteles reported no remaining Phio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 115 Phio Pharmaceuticals shares in Q4 2022, an estimated $7K.
Ergoteles first reported a position in Phio Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Ergoteles's Phio Pharmaceuticals position peaked at $7K in Q3 2022.
10 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.